{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:40Z","timestamp":1786120300308,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/01.cco.0000410158.56500.c4","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T03:54:40Z","timestamp":1323230080000},"page":"S1-S10","source":"Crossref","is-referenced-by-count":19,"title":["Photopheresis in the treatment of cutaneous T-cell lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"John A.","family":"Zic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/archderm.1991.01680090099012","article-title":"Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations.","volume":"127","author":"Rook","year":"1991","journal-title":"Arch Dermatol"},{"key":"R2-1-20210128","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoidesSezary syndrome.","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"R4-1-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","article-title":"U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.","volume":"158","author":"Scarisbrick","year":"2008","journal-title":"Br J Dermatol"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","article-title":"Multicenter photopheresis intervention trial in early-stage mycosis fungoides.","volume":"11","author":"Talpur","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R6-1-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2009.09081.x","article-title":"Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.","volume":"161","author":"Bisaccia","year":"2009","journal-title":"Br J Dermatol"},{"key":"R7-1-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tmrv.2009.09.008","article-title":"Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis.","volume":"24","author":"Voss","year":"2010","journal-title":"Transfus Med Rev"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma.","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts.","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"R10-1-20210128","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R11-1-20210128","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"R12-1-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R13-1-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"R14-1-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008397323199","article-title":"Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features.","volume":"9","author":"Bernengo","year":"1998","journal-title":"Ann Oncol"},{"key":"R15-1-20210128","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoidesSezary syndrome: validation of the revised International Society for Cutaneous LymphomasEuropean Organisation for Research and Treatment of Cancer staging proposal.","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"R16-1-20210128","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome.","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"R17-1-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/107327489800500101","article-title":"Cutaneous T-cell Lymphoma.","volume":"5","author":"Glass","year":"1998","journal-title":"Cancer Control"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and Sezary syndrome.","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides.","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2133.2002.04966.x","article-title":"Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides.","volume":"147","author":"Mao","year":"2002","journal-title":"Br J Dermatol"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood-2010-05-287664","article-title":"High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.","volume":"117","author":"Clark","year":"2011","journal-title":"Blood"},{"key":"R25-1-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis.","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"key":"R26-1-20210128","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0190-9622(96)90118-8","article-title":"Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy.","volume":"35","author":"Zic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R27-1-20210128","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R28-1-20210128","first-page":"764","article-title":"The role of phototherapy in cutaneous T-cell lymphoma.","volume":"9","author":"Pothiawala","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"R29-1-20210128","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2009.02.039","article-title":"Extracorporeal photopheresis: past, present, and future.","volume":"61","author":"Knobler","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R31-1-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results.","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"R32-1-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"R33-1-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","article-title":"Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma.","volume":"350","author":"Dippel","year":"1997","journal-title":"Lancet"},{"key":"R35-1-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1067\/mjd.2002.124069","article-title":"Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sezary syndrome.","volume":"47","author":"Bouwhuis","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R36-1-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/039139880002300109","article-title":"Photopheresis in cutaneous T-cell lymphoma: five-year experience.","volume":"23","author":"Crovetti","year":"2000","journal-title":"Int J Artif Organs"},{"key":"R37-1-20210128","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archderm.138.10.1347","article-title":"Circulating CD4CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"R38-1-20210128","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(05)62067-3","article-title":"Extracorporeal photopheresis in Sezary syndrome.","volume":"350","author":"Russell-Jones","year":"1997","journal-title":"Lancet"},{"key":"R39-1-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2004.12.026","article-title":"Photopheresis does not improve survival in Sezary syndrome patients with bone marrow involvement.","volume":"53","author":"de Misa","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R40-1-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.","volume":"27","author":"Heald","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R41-1-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0781.1999.tb00077.x","article-title":"Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience.","volume":"15","author":"Jiang","year":"1999","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R42-1-20210128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archderm.134.8.1001","article-title":"Extracorporeal photopheresis in Sezary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone.","volume":"134","author":"Fraser-Andrews","year":"1998","journal-title":"Arch Dermatol"},{"key":"R44-1-20210128","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and Sezary syndrome.","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"R46-1-20210128","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1993.01680300143034","article-title":"The sign of Leser-Trelat in association with Sezary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa.","volume":"129","author":"Cohen","year":"1993","journal-title":"Arch Dermatol"},{"key":"R47-1-20210128","first-page":"287","article-title":"Sustained remission of Sezary syndrome.","volume":"12","author":"Bouwhuis","year":"2002","journal-title":"Eur J Dermatol"},{"key":"R48-1-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archderm.139.7.909","article-title":"Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.","volume":"139","author":"Ferenczi","year":"2003","journal-title":"Arch Dermatol"},{"key":"R49-1-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archderm.139.6.771","article-title":"Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.","volume":"139","author":"McGinnis","year":"2003","journal-title":"Arch Dermatol"},{"key":"R50-1-20210128","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2005.02.055","article-title":"Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients.","volume":"52","author":"Bouwhuis","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R52-1-20210128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3816\/CLM.2006.n.063","article-title":"High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome.","volume":"7","author":"Richardson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"R53-1-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-3083.2007.02341.x","article-title":"Acute hyperkeratotic and desquamative reaction in a patient with Sezary syndrome treated with bexarotene.","volume":"22","author":"Bagazgoitia","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R54-1-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000421-199406000-00016","article-title":"Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome: use of dual marker labeling to monitor therapeutic response.","volume":"17","author":"Vonderheid","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"R55-1-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1067\/mjd.2002.124816","article-title":"Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.","volume":"47","author":"Shapiro","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R56-1-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.21166","article-title":"Extracorporeal photopheresis: lighting the way to immunomodulation.","volume":"83","author":"Babic","year":"2008","journal-title":"Am J Hematol"},{"key":"R57-1-20210128","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2133.2000.03857.x","article-title":"Extracorporeal photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma.","volume":"143","author":"Rubegni","year":"2000","journal-title":"Br J Dermatol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.cco.0000410158.56500.c4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:28:02Z","timestamp":1786048082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201201001-00001"}},"subtitle":["current status"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":51,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cco.0000410158.56500.c4","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}